Seqirus
- Company typePrivate
- Founded1916
- HeadquartersMaidenhead, United Kingdom
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
Seqirus firmographics
Firmographics- Name
- Seqirus
- Legal name
- CSL Seqirus
- Website
- https://seqirus.com
- Company type
- Private
- Founded year
- 1916
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Ownership category
- akta.pro rank
Seqirus industry classification
Industry- Product category
- Influenza Vaccines
- akta.pro primary industry
- Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable) (HLAAAEAJ)
- akta.pro secondary industries
- Vaccine Cold Chain, Storage & Distribution (HLAIAEAK), Immunization & Vaccine Access Partnerships (Global Vaccine Alliances) (HLAJAOAF), Immunization & Vaccine Delivery Programs (BPADAIAB)
Keywords
Where Seqirus is headquartered
LocationHeadquarters
- HQ city
- Maidenhead
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Seqirus business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Technology or R&D, Personnel, Infrastructure
Revenue model
- Influenza Vaccines: One of the world's largest influenza vaccine providers, developing and delivering seasonal and pandemic influenza vaccines to government and public health agencies globally.
Go-to-market motion1 record
Seqirus product offering
Product offeringCore offering
CSL Seqirus is one of the world's largest influenza vaccine providers, developing, manufacturing, and delivering seasonal and pandemic influenza vaccines to national governments and public health agencies globally. Operating as a wholly-owned subsidiary of CSL Limited, Seqirus focuses its portfolio on influenza vaccine products derived through CSL's vaccines technology R&D platform, with manufacturing and distribution supported by CSL Group's global infrastructure.
Product overview
CSL Seqirus is a biotechnology company and one of the world's largest influenza vaccine providers, operating as part of the broader CSL group alongside CSL Behring and CSL Vifor. CSL Seqirus focuses on pandemic and seasonal influenza vaccines. The broader CSL portfolio includes: CSL Behring offering plasma-derived and recombinant biotherapies for rare and serious diseases (bleeding disorders, immune deficiencies, hereditary angioedema, Alpha 1 Antitrypsin Deficiency); CSL Seqirus providing influenza vaccines; and CSL Vifor addressing iron deficiency and nephrology. The company operates CSL Plasma, one of the world's largest vertically integrated plasma collection networks, supporting the manufacturing of biotherapeutics delivered to patients in more than 100 countries.
Differentiator
Problem solved
Functional benefit
Products and services
- CSL Seqirus Influenza Vaccines Seasonal and pandemic influenza vaccines developed and manufactured by CSL Seqirus, supplied to national governments and public health agencies for routine immunization and pandemic preparedness programs.
Companies that use Seqirus
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
Seqirus technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Seqirus partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Government of CanadacoreCanada has awarded CSL Seqirus a contract for the development of an influenza pandemic vaccine. This contract is part of Canada's efforts to prepare for future influenza pandemics and enhance its public health response capabilities. The partnership represents a direct government engagement for pandemic preparedness.
Scale indicators2 records
Recent moves4 records
Seqirus competitors and assessment
Company assessmentBroad incumbents
- Pfizer: Pfizer is a major pharmaceutical incumbent with a broad vaccines portfolio and significant influenza vaccine presence, competing against Seqirus for government pandemic and seasonal contracts.
Emerging players
- Bharat Biotech: An Indian vaccine manufacturer with growing influenza and pandemic preparedness capabilities, positioning itself as a cost-competitive alternative to Seqirus in emerging-market public health tenders.
- Novavax: Novavax applies recombinant nanoparticle technology to influenza vaccine development, positioning it as an emerging alternative approach that could compete with Seqirus in select markets.
- Moderna: Moderna is developing mRNA-based influenza vaccine candidates that, if approved, would compete directly with Seqirus's traditional influenza vaccine portfolio, representing a potential technology disruption.
Direct peers
- Sanofi Pasteur: Sanofi's vaccines division is one of the world's largest influenza vaccine manufacturers (e.g., Fluzone). Directly competes with Seqirus in seasonal and pandemic flu vaccines sold to governments and public health agencies globally.
- GSK: GSK's vaccines business markets major influenza vaccines (Fluarix, Flulaval) and competes directly with Seqirus across both seasonal and pandemic influenza procurement channels.
- AstraZeneca (FluMist): AstraZeneca markets FluMist, a live attenuated influenza vaccine, positioning it as a direct competitor in the influenza vaccine market that Seqirus serves.
Regional players
- CSK (Kitasato Daiichi Sankyo Vaccines): A leading Japanese influenza vaccine manufacturer serving primarily the Japanese domestic market, offering a regional comparison point for Seqirus's pandemic and seasonal influenza business.
- Sinovac Biotech: A major Chinese vaccine manufacturer with an influenza vaccine franchise, primarily competing in Asian markets but with growing global aspirations that could intersect with Seqirus's footprint.
- Hualan Biological Engineering: One of China's largest influenza vaccine manufacturers, serving primarily the Chinese public health market but with growing export ambitions that could pressure Seqirus in price-sensitive geographies.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Seqirus social profiles
Digital presenceSeqirus financial estimates
Financial estimateRevenue estimate
Valuation estimate
Seqirus leadership team
Management profileNumber of profiles
Seqirus funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Seqirus M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Seqirus
What does Seqirus do?
CSL Seqirus is one of the world's largest influenza vaccine providers, developing, manufacturing, and delivering seasonal and pandemic influenza vaccines to national governments and public health agencies globally. Operating as a wholly-owned subsidiary of CSL Limited, Seqirus focuses its portfolio on influenza vaccine products derived through CSL's vaccines technology R&D platform, with manufacturing and distribution supported by CSL Group's global infrastructure.
Is Seqirus a public or private company?
Seqirus is a private company. It is classified as corporate owned and is currently operating.
When was Seqirus founded?
Seqirus was founded in 1916. It employs 1,001 to 5,000 people.
Where is Seqirus based?
Seqirus is headquartered in Maidenhead, United Kingdom, in the Europe region.
How does Seqirus make money?
One revenue line is on record: influenza Vaccines.
Who are Seqirus's main competitors?
Pfizer is listed as a broad incumbent. Emerging players are Bharat Biotech, Novavax and Moderna. Direct peers are Sanofi Pasteur, GSK and AstraZeneca (FluMist). Regional players are CSK (Kitasato Daiichi Sankyo Vaccines), Sinovac Biotech and Hualan Biological Engineering.
Does Seqirus have an API?
No public API is recorded for Seqirus.
What industry is Seqirus in?
Seqirus's product category is Influenza Vaccines. Its primary akta.pro industry code is HLAAAEAJ, Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable), with a secondary code of HLAIAEAK, Vaccine Cold Chain, Storage & Distribution.